Work

A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data

Year: 2025

Type: article

Abstract: Objective This retrospective natural history study used real-world data to describe baseline demographics, comorbidities, clinical characteristics, and treatments, and assess incidence rates (IRs) of extra-muscular outcomes in patients with incident dermatomyositis (DM), polymyositis (PM), juvenile DM (JDM), and juvenile PM (JPM). Methods De-identified clinical data were collected from the US Optum® electronic health records with supplemental claims (01 January 2016 to 31 March 2021). Total 9,009 patients were included (DM: 4,275; PM: 4,559; JDM: 128; JPM: 47). IRs of 13 outcomes were estimated in patients and an equal number of sex- and age-matched controls (MCs) without DM/PM. Results Mean age at index was 54.5 (DM), 57.3 (PM), 14.3 (JDM), and 15.1 years (JPM). Most common comorbidities were hypertension in DM (50.3%) and PM (63.9%) cohorts, dysphagia in JDM (15.6%) and liver disease in JPM (23.4%) cohorts. Most common clinical characteristics were Raynaud’s phenomenon in DM (8.6%), PM (7.9%), and JDM (11.7%) cohorts, and arthritis in JPM (10.6%) cohort. Systemic steroids were the most frequent medication (DM: 70.3%; PM: 68.3%; JDM: 73.4%; JPM: 59.6%). IRs (per 100 person years) of outcomes in all cohorts were higher in patients versus their MCs. In DM and PM cohorts, highest IRs were observed for gastroesophageal reflux disease (DM:10.3; PM:12.8). In JDM cohort, dysphagia (4.3) had highest IR. In JPM cohort, cardiac dysrhythmia (3.5) had highest IR. Conclusion This study addresses existing gaps in understanding the descriptive epidemiology of DM and PM in the US, particularly the IRs of extra-muscular disease manifestations and malignancy events. Key Points • This study provides a comprehensive description of demographic and disease characteristics in a large and nationally representative sample of adult and juvenile patients with incident DM and PM in the US. • The results cover wide arrays of demographics, comorbidities, clinical characteristics, treatment exposures, and extra-muscular disease manifestations and malignancies in patients with incident DM and PM. • The results frequently align with findings from other, smaller studies in patients with myositis.

Source: Clinical Rheumatology

DOI: 10.1007/s10067-025-07614-6

Authors: David M. Barnes, Daniela Graham, Cecilia E. Borlenghi, Thomas Edwards, Stephen E. Schachterle, Helen Sile

Institution: Pfizer (United States)

Language: English

Topic: Inflammatory Myopathies and Dermatomyositis

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,890